LOG IN/REGISTER >
FORWARD TO A COLLEAGUE >
INDICATION/SAFETY INFORMATION >

Telestroke networks throughout the United States

Telestroke networks may be found in more than 20 states across the country. New telestroke networks can further expand the reach of specialized stroke care to rural and underserved areas of the United States.*

Interactive map

Roll over dots to view telestroke systems. Click on selected pop-up labels to visit center Web sites.

Review case studies with more detailed information about 2 telestroke networks.

  • *
  • Network information current as of August 2009 from various sources including AHA recommendations listed as reference 1.


SUBMIT YOUR TELESTROKE NETWORK



Indication
Activase (Alteplase) is indicated for the management of acute ischemic stroke in adults for improving neurological recovery and reducing the incidence of disability. Treatment should only be initiated within 3 hours after the onset of stroke symptoms, and after exclusion of intracranial hemorrhage by a cranial computerized tomography (CT) scan or other diagnostic imaging method sensitive for the presence of hemorrhage (see CONTRAINDICATIONS).

Important Safety Information
Activase therapy in patients with AIS is contraindicated in certain situations (eg, suspicion of subarachnoid hemorrhage on pretreatment evaluation, recent (within 3 months) intracranial or intraspinal surgery, history of intracranial hemorrhage, uncontrolled hypertension at time of treatment, active internal bleeding, known bleeding diathesis (eg, current use of oral anticoagulants, administration of heparin within 48 hours of onset of stroke, platelet count <100,000) (see CONTRAINDICATIONS for full list).

The most common complication during Activase therapy is bleeding. Should serious bleeding in a critical location (intracranial, gastrointestinal, retroperitoneal, pericardial) occur, Activase therapy should be discontinued immediately. Death and permanent disability are not uncommonly reported in patients who have experienced stroke (including intracranial bleeding) and other serious bleeding episodes.

The risks of Activase therapy may be increased and should be weighed against the anticipated benefits in certain conditions. [See WARNINGS in full prescribing information].

  • Patients with severe neurological deficit (eg, NIHSS >22) at presentation. There is an increased risk of intracranial hemorrhage in these patients.
  • Patients with major early infarct signs on a computerized cranial tomography (CT) scan (eg, substantial edema, mass effect, or midline shift).

Treatment of patients with minor neurological deficit or with rapidly improving symptoms is not recommended.

Orolingual angioedema has been observed in postmarketing experience in patients treated with Activase for AIS. Patients should be monitored during and for several hours after infusion for signs of orolingual angioedema.

Please click here for full prescribing information.
References:
1.
Schwamm LH, Audebert HJ, Amarenco P, et al. Recommendations for the implementation of telemedicine within stroke systems of care: a policy statement from the American Heart Association. Stroke. 2009;40. http://stroke.ahajournals.org/cgi/reprint/STROKEAHA.109.192361v1. Accessed May 7, 2009.
2.
Partners TeleStroke Center. Member Hospitals. Partners Telestroke Center Web site. http://telestroke.massgeneral.org/phsMembers.aspx. Accessed July 22, 2009.
3.
Medical College of Georgia. MCG stroke/telestroke network. Medical College of Georgia Web site. http://www.mcg.edu/neurology/specialties/stroke/telestroke.html. Updated December 10, 2008. Accessed July 28, 2009.